Tesofensine: Triple Monoamine Reuptake Inhibitor for Weight Loss

Disclaimer: This article is for informational and educational purposes only. Tesofensine is an investigational compound not approved by the FDA for any indication. It is sold exclusively as a research chemical and is not intended for human consumption. Readers should consult a qualified healthcare provider before considering any pharmacological intervention. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation.

About the Author: Dr. Alexander Isaacs is a scientific writer and research consultant specializing in peptide biochemistry, pharmacology of research compounds, and preclinical data analysis. His work is published on the Grey Research Peptides blog. All claims in this article are grounded in published clinical and preclinical data.

Key Takeaways

• What it is: A centrally acting small-molecule triple monoamine reuptake inhibitor targeting dopamine, norepinephrine, and serotonin transporters.
• Efficacy: Phase 2 data yielded significant body weight loss — up to roughly 10.6% at the 1.0 mg dose over 24 weeks.
• Core Mechanism: Combines central appetite suppression with increased sympathomimetic thermogenesis.
• Primary Risk: Dose-dependent cardiovascular signals, notably elevated heart rate and blood pressure.
• Regulatory Status: Investigational research compound; not FDA-approved.
• Sourcing: Requires rigorous verification of third-party HPLC and mass spectrometry Certificates of Analysis (COA).

1. What Is Tesofensine and How Was It Discovered?

Tesofensine (originally NS2330) is a centrally acting triple monoamine reuptake inhibitor. It was synthesized by NeuroSearch A/S for neurodegenerative diseases like Parkinson’s and Alzheimer’s. The compound belongs to the phenyltropane chemical class, making it structurally related to certain tropane alkaloids.

The Serendipitous Pivot

During Phase 2 trials for Parkinson’s, researchers noticed that subjects experienced unexpected and clinically significant weight loss. NeuroSearch subsequently pivoted the compound from neurodegenerative research to a dedicated anti-obesity program called TIPO (Tesofensine In the treatment of People with Obesity).

Fact Check: Why Tesofensine Is Not a Peptide

Despite being sold by peptide vendors, tesofensine is a small-molecule organic compound, not a peptide. It contains no amino acids or peptide bonds. It has a molecular weight of approximately 382.5 g/mol. It does not require reconstitution in bacteriostatic water and has a different stability profile than lyophilized peptides.

2. Mechanism of Action: Affecting Three Neurotransmitter Systems

Tesofensine inhibits the presynaptic reuptake of three neurotransmitters. It follows a distinct binding hierarchy:

• Norepinephrine (Strongest — IC50 ~1.7 nM): Drives thermogenesis and increases resting metabolic rate.
• Dopamine (IC50 ~6.5 nM): Modulates reward circuitry, reducing the hedonic drive to eat.
• Serotonin (IC50 ~11.0 nM): Enhances satiety signaling in the hypothalamus.

Appetite Suppression

Preclinical research shows tesofensine “silences” GABAergic hypothalamic neurons that normally promote feeding. Unlike some other agents, it reduces the motivational “wanting” of food without altering the sensory “liking” (taste) of it.

Thermogenesis

By blocking norepinephrine reuptake, it stimulates the sympathetic nervous system to increase heat generation and basal energy expenditure.

3. Tesofensine Weight Loss: Clinical Trial Evidence

The most cited evidence comes from the TIPO-1 Phase 2 trial (Astrup et al., 2008), a 24-week study of 203 obese patients.

Phase 2 Trial Outcomes (24 Weeks)

• Placebo: ~2.0% weight loss.
• Tesofensine 0.25 mg: ~4.5% weight loss.
• Tesofensine 0.5 mg: ~9.2% weight loss.
• Tesofensine 1.0 mg: ~10.6% weight loss.

The 0.5 mg dose is generally considered the “sweet spot” for research, as the 1.0 mg dose produced significantly higher dropout rates due to cardiovascular side effects.

4. Tesofensine vs. Other Compounds

While semaglutide and tirzepatide show higher total weight loss, they are injectables and often cause gastrointestinal distress. Tesofensine offers an oral alternative with a purely neurological (CNS) mechanism.

5. Side Effects and Cardiovascular Risk

Tesofensine’s primary hurdle to FDA approval is its cardiovascular profile:

• Common Effects: Dry mouth, insomnia, nausea, constipation, and headache.
• Cardiovascular Signals: At 1.0 mg, patients saw a mean heart rate increase of 7–8 beats per minute and modest blood pressure elevation.

Critical Safety Warnings

• MAOIs: Strict contraindication; risk of hypertensive crisis and serotonin syndrome.
• SSRIs/SNRIs: Risk of serotonin syndrome.
• Stimulants: Compounding cardiovascular stress.

6. Pharmacokinetics: The Long Half-Life

Tesofensine is exceptionally long-acting:

• Elimination Half-Life: 8–12 days (200–300 hours).
• Time to Steady State: 4–8 weeks of daily dosing.
• Washout Period: 45–60 days to completely clear the system.

Because of this, weight loss results are not immediate; they build gradually over the first month as plasma levels accumulate. Conversely, if side effects occur, they persist for weeks after the last dose is taken.

7. FDA Status and Regulatory Pathway

Tesofensine is NOT FDA-approved.

The regulatory barrier became insurmountable after the 2010 withdrawal of sibutramine. Regulators now require massive, expensive Cardiovascular Outcome Trials (CVOTs) for CNS-active weight loss drugs. Most small biotech companies lack the capital for these trials, leaving tesofensine in “regulatory limbo.”

8. Frequently Asked Questions

Can you buy Tesofensine legally?

It is not approved for human use. It is sold legally only “for in-vitro laboratory research and R&D use.”

How do you verify quality?

Look for batch-specific, third-party HPLC/Mass Spec testing. Purity should be >99% with a sharp, single peak on the chromatogram, and mass spectrometry should confirm a molecular weight of ~382.5 g/mol.

Does it compare to sibutramine?

Sibutramine was a dual reuptake inhibitor; tesofensine is a triple inhibitor (adding dopamine). Tesofensine appears more potent for weight loss but carries similar cardiovascular concerns.

References

• Astrup A, et al. “Effect of tesofensine on bodyweight loss… a randomised, double-blind, placebo-controlled trial.” The Lancet (2008).
• Axel AM, et al. “Tesofensine… induces appetite suppression by indirect stimulation of alpha-1 adrenoceptor and dopamine D1 receptor pathways…” Neuropsychopharmacology (2010).
• Perez CI, et al. “Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.” PLoS ONE (2024).
• James WPT, et al. “Effect of sibutramine on cardiovascular outcomes…” NEJM (2010).